학술논문
D27 - Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2016 27 Supplement 4:iv47-iv47
Subject
Language
ISSN
0923-7534